896 related articles for article (PubMed ID: 23891824)
1. Peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms in nonalcoholic fatty liver disease: a study in Brazilian patients.
Domenici FA; Brochado MJ; Martinelli Ade L; Zucoloto S; da Cunha SF; Vannucchi H
Gene; 2013 Oct; 529(2):326-31. PubMed ID: 23891824
[TBL] [Abstract][Full Text] [Related]
2. Association between resistin +299A/A genotype and nonalcoholic fatty liver disease in Chinese patients with type 2 diabetes mellitus.
Zhang LY; Jin YJ; Jin QS; Lin LY; Zhang DD; Kong LL
Gene; 2013 Oct; 529(2):340-4. PubMed ID: 23954219
[TBL] [Abstract][Full Text] [Related]
3. Association between the Pro12Ala polymorphism of PPAR-γ gene and the non-alcoholic fatty liver disease: a meta-analysis.
Wang J; Guo X; Wu P; Song J; Ye C; Yu S; Zhang J; Dong W
Gene; 2013 Oct; 528(2):328-34. PubMed ID: 23891820
[TBL] [Abstract][Full Text] [Related]
4. Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study.
Dongiovanni P; Rametta R; Fracanzani AL; Benedan L; Borroni V; Maggioni P; Maggioni M; Fargion S; Valenti L
BMC Gastroenterol; 2010 Sep; 10():102. PubMed ID: 20825652
[TBL] [Abstract][Full Text] [Related]
5. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptor alpha L162V polymorphism in nonalcoholic steatohepatitis and genotype 1 hepatitis C virus-related liver steatosis.
Verdi H; Koytak ES; Onder O; Ergül AA; Cinar K; Idilman R; Erden E; Bozdayi AM; Yurdaydin C; Uzunalimoglu O; Bozkaya H
J Investig Med; 2005 Nov; 53(7):353-9. PubMed ID: 16297361
[TBL] [Abstract][Full Text] [Related]
7. Association between Pro12Ala polymorphism of the PPAR-gamma2 gene and insulin sensitivity in Brazilian patients with type-2 diabetes mellitus.
Tavares V; Hirata RD; Rodrigues AC; Monte O; Salles JE; Scalissi N; Speranza AC; Hirata MH
Diabetes Obes Metab; 2005 Sep; 7(5):605-11. PubMed ID: 16050954
[TBL] [Abstract][Full Text] [Related]
8. Association between angiotensin II type 1 receptor polymorphisms and the occurrence of nonalcoholic fatty liver disease.
Yoneda M; Hotta K; Nozaki Y; Endo H; Uchiyama T; Mawatari H; Iida H; Kato S; Fujita K; Takahashi H; Kirikoshi H; Kobayashi N; Inamori M; Abe Y; Kubota K; Saito S; Maeyama S; Wada K; Nakajima A
Liver Int; 2009 Aug; 29(7):1078-85. PubMed ID: 19302184
[TBL] [Abstract][Full Text] [Related]
9. PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis.
Francque S; Verrijken A; Caron S; Prawitt J; Paumelle R; Derudas B; Lefebvre P; Taskinen MR; Van Hul W; Mertens I; Hubens G; Van Marck E; Michielsen P; Van Gaal L; Staels B
J Hepatol; 2015 Jul; 63(1):164-73. PubMed ID: 25703085
[TBL] [Abstract][Full Text] [Related]
10. Effects of two common polymorphisms of peroxisome proliferator-activated receptor-gamma gene on metabolic syndrome.
Rhee EJ; Oh KW; Lee WY; Kim SY; Oh ES; Baek KH; Kang MI; Kim SW
Arch Med Res; 2006 Jan; 37(1):86-94. PubMed ID: 16314192
[TBL] [Abstract][Full Text] [Related]
11. PPARG gene Pro12Ala variant contributes to the development of non-alcoholic fatty liver in middle-aged and older Chinese population.
Yang Z; Wen J; Li Q; Tao X; Ye Z; He M; Zhang W; Huang Y; Chen L; Ling C; Qu S; Hu R
Mol Cell Endocrinol; 2012 Jan; 348(1):255-9. PubMed ID: 21939732
[TBL] [Abstract][Full Text] [Related]
12. Association of polymorphisms of glutamate-cystein ligase and microsomal triglyceride transfer protein genes in non-alcoholic fatty liver disease.
Oliveira CP; Stefano JT; Cavaleiro AM; Zanella Fortes MA; Vieira SM; Rodrigues Lima VM; Santos TE; Santos VN; de Azevedo Salgado AL; Parise ER; Ferreira Alves VA; Carrilho FJ; Corrêa-Giannella ML
J Gastroenterol Hepatol; 2010 Feb; 25(2):357-61. PubMed ID: 19817962
[TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.
Larter CZ; Yeh MM; Van Rooyen DM; Brooling J; Ghatora K; Farrell GC
J Gastroenterol Hepatol; 2012 Feb; 27(2):341-50. PubMed ID: 21929649
[TBL] [Abstract][Full Text] [Related]
14. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Staels B; Rubenstrunk A; Noel B; Rigou G; Delataille P; Millatt LJ; Baron M; Lucas A; Tailleux A; Hum DW; Ratziu V; Cariou B; Hanf R
Hepatology; 2013 Dec; 58(6):1941-52. PubMed ID: 23703580
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis.
Svegliati-Baroni G; Saccomanno S; Rychlicki C; Agostinelli L; De Minicis S; Candelaresi C; Faraci G; Pacetti D; Vivarelli M; Nicolini D; Garelli P; Casini A; Manco M; Mingrone G; Risaliti A; Frega GN; Benedetti A; Gastaldelli A
Liver Int; 2011 Oct; 31(9):1285-97. PubMed ID: 21745271
[TBL] [Abstract][Full Text] [Related]
16. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
Cong WN; Tao RY; Tian JY; Liu GT; Ye F
Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155
[TBL] [Abstract][Full Text] [Related]
17. Methylenetetrahydrofolate reductase gene polymorphisms in patients with nonalcoholic steatohepatitis (NASH).
Sazci A; Ergul E; Aygun C; Akpinar G; Senturk O; Hulagu S
Cell Biochem Funct; 2008 Apr; 26(3):291-6. PubMed ID: 17563923
[TBL] [Abstract][Full Text] [Related]
18. Altered hepatic expression of SREBP-1 and PPARgamma is associated with liver injury in insulin-resistant lipodystrophic HIV-infected patients.
Lemoine M; Barbu V; Girard PM; Kim M; Bastard JP; Wendum D; Paye F; Housset C; Capeau J; Serfaty L
AIDS; 2006 Feb; 20(3):387-95. PubMed ID: 16439872
[TBL] [Abstract][Full Text] [Related]
19. Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity.
Fracanzani AL; Valenti L; Bugianesi E; Vanni E; Grieco A; Miele L; Consonni D; Fatta E; Lombardi R; Marchesini G; Fargion S
J Hepatol; 2011 Jun; 54(6):1244-9. PubMed ID: 21145841
[TBL] [Abstract][Full Text] [Related]
20. The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice.
Pawlak M; Baugé E; Bourguet W; De Bosscher K; Lalloyer F; Tailleux A; Lebherz C; Lefebvre P; Staels B
Hepatology; 2014 Nov; 60(5):1593-606. PubMed ID: 24995693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
